Robert I. Nicholson

Biochemistry, Genetics and Molecular Biology · Life Sciences

84h-index23.7kcitations383works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Estrogen and related hormone effects(188), HER2/EGFR in Cancer Research(91), Breast Cancer Treatment Studies(36), Cancer Cells and Metastasis(26), Growth Hormone and Insulin-like Growth Factors(24)

Publications383 total

To Void or Not to Void After Minimally Invasive Benign Hysterectomy: That Is the Question
Journal of Minimally Invasive Gynecology·2024
Supplementary Figure 2 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Data from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Materials and Methods from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 3 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 5 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure Legends from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 1 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 2 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 5 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Data from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 6 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 1 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure Legends from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Materials and Methods from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Figure 4 from BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer
2023Open Access
Supplementary Tables S1-10 from Reprogramming of the ERRα and ERα Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Julia M.W. Gee(22), Ian O. Ellis(16), J.F.R. Robertson(13), Denise Barrow(10), KM Taylor(9), R.W. Blamey(8), Janice M. Knowlden(6), Iain R. Hutcheson(6), Stephen Hiscox(5), R A McClelland(5), Sarah E. Pinder(4), Joshua A. Bell(4), A. E. Wakeling(4), Roger W. Blamey(4), Richard A. McClelland(4), Helen Morgan(4), M. E. Harper(3), Helen E. Jones(3), Tracie‐Ann Madden(3), Pauline Finlay(3)